Wockhardt Limited announced strong performance for the third quarter of the Financial Year 2025-26, ending December 31, 2025. The company achieved a 22% growth in revenue, reaching INR 888 Cr, alongside a substantial 72% surge in EBITDA to INR 173 Cr. Key segments like Biotech showed exceptional 96% YoY growth, while pipeline achievements, including the completion of the Phase III trial for ZAYNICH®, signal strong future potential in novel antibiotics.
Q3 FY26 Financial Acceleration
Wockhardt Limited, a major player in Pharmaceutical and Biotechnology, reported robust financial results for the third quarter ending December 31, 2025. Total Revenue for Q3 FY26 stood at INR 888 Cr, marking a significant 22% increase compared to the previous year’s INR 725 Cr. EBITDA also saw dramatic growth, surging 72% year-over-year to reach INR 173 Cr, up from INR 100 Cr in Q3 FY25.
For the nine months ending December 31, 2025 (9M FY26), Total Revenue reached INR 2,408 Cr, with EBITDA standing at INR 434 Cr, representing an 18.0% margin. Profit Before Tax (PBT) for the quarter was INR 67 Cr, significantly higher than the INR 21 Cr recorded in the previous year. PAT Margin for Q3 FY26 improved to 6.9%.
Segment Performance and Innovation
Biosimilar Highlights
The Biotech business demonstrated exceptional performance, with operations for the quarter reaching INR 213 Cr. This represents a remarkable 96% growth compared to Q4 FY25 (INR 109 Cr) and 38% growth versus Q2 FY26 (INR 154 Cr). This robust achievement is being fueled by the Emerging Market biotech segment, which grew at > 50%.
Business Highlights by Geography
The company saw strong growth across key international regions:
- India Branded Business: Grew by 28% to Rs.146 crore in Q3 FY26, driven by Diabetic therapy and the launch of the Regenerative Derma segment.
- UK Region: Reported Rs.343 crore, a 15% growth year-over-year.
- Emerging Markets Region: Grew by an impressive 48% to Rs.264 crore, mainly supported by the Biotech Insulin segment.
- Irish Region: Increased by 23% to Rs.57 crore.
Innovative Portfolio Contribution
The innovative portfolio contributed 26.3% of Revenue in Q3 FY26 and 22% in 9M FY26, spanning Novel Antibiotics, Biotechnology, and Pharmaceuticals.
Pipeline and New Product Updates
Novel Antibiotics Key Updates
ZAYNICH®: The Global Phase III clinical study was successfully completed. It demonstrated 97% clinical efficacy and reported 20% superiority over gold standard Meropenem. A crucial breakpoint of 64 mg/L was granted by CLSI, USA, for all major gram-negative pathogens.
The Marketing Authorisation Application (MAA) was submitted to the European Medicines Agency (EMA) in January 2026, which has already granted an Accelerated Assessment recognizing Zaynich’s potential against resistant Gram-negative infections.
MIQNAF® NAFITHROMYCIN: This product has been approved and launched in India. The removal of the “supply condition” by DCGI now facilitates wider marketing access. The product shows a 97% Success Rate in Community Acquired Pneumonia and offers an Ultra Short 3-Day Treatment.
EMROK®/EMROK O®: These brands continue to show strong traction, with a growth rate of 52% versus previous year Q3, having treated approximately 140,000 patients to date.
FOVISCU® (WCK 4282) Milestone
The India Phase III trial was completed successfully, matching the gold-standard Meropenem. FOVISCU achieved a Clinical cure rate of 93.23% versus Meropenem’s 92.31% in treating complicated urinary tract infections (cUTI) and acute pyelonephritis.
Intellectual Property Update
During the quarter, 4 new patents were filed. The cumulative filings as of December 31, 2025, stand at 3,289, and the company currently holds 858 patents.
Source: BSE
